Hologic, Inc.

BIT:1HOLX Stock Report

Market Cap: €11.2b

Hologic Valuation

Is 1HOLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1HOLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€127.42
Fair Value
60.8% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: 1HOLX (€50) is trading below our estimate of fair value (€127.42)

Significantly Below Fair Value: 1HOLX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1HOLX?

Key metric: As 1HOLX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1HOLX. This is calculated by dividing 1HOLX's market cap by their current earnings.
What is 1HOLX's PE Ratio?
PE Ratio22.7x
EarningsUS$556.70m
Market CapUS$12.65b

Price to Earnings Ratio vs Peers

How does 1HOLX's PE Ratio compare to its peers?

The above table shows the PE ratio for 1HOLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average19.7x
DIA DiaSorin
26.5x12.6%€5.1b
ELN EL.En
12x2.0%€743.1m
AMP Amplifon
29.4x14.3%€4.2b
IMD I.M.D. International Medical Devices
11xn/a€24.6m
1HOLX Hologic
22.7x15.4%€12.6b

Price-To-Earnings vs Peers: 1HOLX is expensive based on its Price-To-Earnings Ratio (22.7x) compared to the peer average (19.7x).

Price to Earnings Ratio vs Industry

How does 1HOLX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1HOLX 22.7xIndustry Avg. 30.7xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1HOLX is good value based on its Price-To-Earnings Ratio (22.7x) compared to the European Medical Equipment industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1HOLX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1HOLX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1HOLX's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1HOLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€50.00
€60.04
+20.1%
9.2%€75.10€53.01n/a14
May ’26€51.00
€66.69
+30.8%
9.4%€79.71€57.57n/a15
Apr ’26n/a
€72.79
0%
7.7%€83.42€64.88n/a16
Mar ’26n/a
€77.68
0%
8.0%€91.64€67.52n/a16
Feb ’26n/a
€81.34
0%
8.4%€91.07€67.10n/a17
Jan ’26n/a
€82.81
0%
7.9%€91.63€67.52n/a17
Dec ’25n/a
€79.83
0%
7.2%€87.87€64.07n/a15
Nov ’25n/a
€80.21
0%
7.0%€88.37€64.44n/a16
Oct ’25n/a
€78.54
0%
7.9%€86.73€63.24n/a15
Sep ’25n/a
€79.78
0%
8.6%€87.96€64.14n/a15
Aug ’25n/a
€80.16
0%
8.6%€88.96€64.87n/a14
Jul ’25n/a
€79.84
0%
7.6%€88.95€65.54n/a15
Jun ’25n/a
€78.39
0%
7.8%€87.47€64.45n/a14
May ’25n/a
€78.98
0%
7.6%€89.03€65.60€51.0015
Apr ’25n/a
€76.65
0%
7.6%€88.07€64.90n/a15
Mar ’25n/a
€76.65
0%
7.6%€88.07€64.90n/a15
Feb ’25n/a
€74.88
0%
7.5%€87.40€64.40n/a15
Jan ’25n/a
€72.53
0%
8.1%€86.05€63.41n/a16
Dec ’24n/a
€73.19
0%
8.5%€87.11€64.18n/a16
Nov ’24n/a
€78.88
0%
9.1%€89.98€66.30n/a15
Oct ’24n/a
€82.39
0%
8.1%€88.61€65.29n/a15
Sep ’24n/a
€81.77
0%
8.1%€87.94€64.80n/a15
Aug ’24n/a
€80.85
0%
8.1%€89.23€63.74n/a15
Jul ’24n/a
€82.65
0%
8.9%€95.33€63.55n/a14
Jun ’24n/a
€82.65
0%
8.9%€95.33€63.55n/a14
May ’24n/a
€79.85
0%
7.9%€86.59€63.81n/a14
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
€59.88
Fair Value
16.5% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 08:28
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/29
Annual Earnings2024/09/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hologic, Inc. is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays